-+ 0.00%
-+ 0.00%
-+ 0.00%

Sirnaomics unit RNAimmune Vaccine signs shareholder agreement with Guangzhou Guangjian fund for RMB 30 million investment

PUBT·08/26/2026 11:06:28
Listen to the news
Sirnaomics unit RNAimmune Vaccine signs shareholder agreement with Guangzhou Guangjian fund for RMB 30 million investment
  • Sirnaomics signed a shareholders’ agreement for RNAimmune Vaccine (Guangzhou) tied to a RMB 30 million equity investment.
  • Deal dilutes RNAimmune, Inc. to 94.34% from 100%, leaving the investor with 5.66% at a RMB 500 million pre-money valuation.
  • Investor gains a repurchase right if no Qualified IPO by Dec. 31, 2032, or no approved restructuring by Dec. 31, 2028.
  • Redemption price set at up to RMB 30 million, plus 8% simple annual interest, minus any dividends or distributions received.
  • Transaction keeps the unit consolidated; Sirnaomics’ effective interest falls to 56.8% from 60.21%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300531), on August 26, 2026, and is solely responsible for the information contained therein.